Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

BioPorto Management

Management Kriterienprüfungen 3/4

BioPorto's CEO ist Peter Eriksen, ernannt in Jan 2024, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.035% der Aktien des Unternehmens, im Wert von DKK230.81K. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 0.9 Jahre bzw. 10.3 Jahre.

Wichtige Informationen

Peter Eriksen

Geschäftsführender

kr.292.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.03%
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	10.3yrs

Jüngste Management Updates

Recent updates

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Oct 16

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

May 28

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

Mar 01

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

Jan 24

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

Dec 20

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

Nov 23

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Nov 21

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Peter Eriksen im Vergleich zu den Einnahmen von BioPorto verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-kr.54m
Dec 31 2023	n/a	n/a	-kr.56m
Sep 30 2023	n/a	n/a	-kr.70m
Jun 30 2023	n/a	n/a	-kr.78m
Mar 31 2023	n/a	n/a	-kr.75m
Dec 31 2022	kr.292k	n/a	-kr.76m
Sep 30 2022	n/a	n/a	-kr.68m
Jun 30 2022	n/a	n/a	-kr.62m
Mar 31 2022	n/a	n/a	-kr.59m
Dec 31 2021	kr.3m	n/a	-kr.57m
Sep 30 2021	n/a	n/a	-kr.54m
Jun 30 2021	n/a	n/a	-kr.60m
Mar 31 2021	n/a	n/a	-kr.62m
Dec 31 2020	kr.7m	kr.3m	-kr.62m
Sep 30 2020	n/a	n/a	-kr.64m
Jun 30 2020	n/a	n/a	-kr.68m
Mar 31 2020	n/a	n/a	-kr.69m
Dec 31 2019	kr.6m	kr.3m	-kr.70m
Sep 30 2019	n/a	n/a	-kr.61m
Jun 30 2019	n/a	n/a	-kr.51m
Mar 31 2019	n/a	n/a	-kr.43m
Dec 31 2018	kr.4m	kr.3m	-kr.38m
Sep 30 2018	n/a	n/a	-kr.38m
Jun 30 2018	n/a	n/a	-kr.36m
Mar 31 2018	n/a	n/a	-kr.35m
Dec 31 2017	kr.5m	kr.3m	-kr.32m

Vergütung im Vergleich zum Markt: PeterDie Gesamtvergütung ($USD42.51K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Danish ($USD355.51K).

Entschädigung vs. Einkommen: PeterDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Peter Eriksen (63 yo)

less than a year

Amtszeit

kr.292,000

Vergütung

Mr. Peter Morch Eriksen, BBA, serves as Chief Executive Officer at BioPorto A/S. He served as a Director of BioPorto A/S since November 15, 2021 until April 30, 2024 and served as its Interim CEO from Janu...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Peter Eriksen	Chief Executive Officer	less than a year	kr.292.00k	0.035% DKK 225.5k
Lars Uttenthal	Chief Scientific Officer	no data	keine Daten	keine Daten
Gry Larsen	Executive VP & Chief Legal Officer	less than a year	keine Daten	keine Daten
Jennifer Zonderman	SVP of Global Marketing & US Commercialization	5yrs	keine Daten	keine Daten
Nis Kruse	Executive VP of Strategic Partnerships and GM of EMEA & APAC	1.4yrs	keine Daten	keine Daten

0.9yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: BIOPORDas Führungsteam des Unternehmens gilt nicht als erfahren (0.9 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Donnie Hardison	Independent Vice Chairman of the Board	3.1yrs	kr.795.00k	keine Daten
John McDonough	Independent Chairman of the Board	3.1yrs	kr.1.08m	0.046% DKK 299.2k
Claudio Ronco	Member of Scientific Advisory Board	10.3yrs	keine Daten	keine Daten
Mats Thoren	Director	no data	keine Daten	keine Daten
Jean-Louis Vincent	Chairman of the Scientific Advisory Board	10.3yrs	keine Daten	keine Daten
Henrik Juuel	Director	no data	keine Daten	keine Daten
Ninfa Saunders	Independent Director	1.1yrs	kr.458.00k	keine Daten
Michael Singer	Independent Director	4.8yrs	kr.674.00k	0.055% DKK 357.9k
Andrew Lewington	Vice Chairman of Scientific Advisory Board	10.3yrs	keine Daten	keine Daten
Laurent Jacob	Member of Scientific Advisory Board	10.3yrs	keine Daten	keine Daten
Michael Haase	Member of Scientific Advisory Board	10.3yrs	keine Daten	keine Daten
Hilde Geus	Member of Scientific Advisory Board	10.3yrs	keine Daten	keine Daten

10.3yrs

Durchschnittliche Betriebszugehörigkeit

60.5yo

Durchschnittliches Alter

Erfahrener Vorstand: BIOPORDie Vorstandsmitglieder sind sehr erfahren ( 10.3 ).

BioPorto Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

BioPorto A/S Announces CEO Changes

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Bioporto A/S Announces Resignation of Neil Goldman as CFO

Recent updates

Bioporto A/S Provides Revenue Guidance for 2024

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

BioPorto A/S Announces CEO Changes

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

New major risk - Share price stability

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Consensus estimates of losses per share improve by 16%

New major risk - Financial position

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioPorto A/S Maintains Earnings Guidance for the Year 2023

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

BioPorto A/S, Annual General Meeting, Apr 27, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Price target decreased to kr.3.50

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)

BioPorto A/S Maintains Earnings Guidance for the Year 2021

BioPorto A/S Provides Pipeline Update Regarding COVID-19 Test

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr.0.06 loss per share (vs kr.0.088 loss in 1Q 2020)

BioPorto A/S Provides Earning Guidance for the Year 2021

Independent Vice Chairman Torben Nielsen has left the company

Independent Director has left the company

Price target decreased to kr.6.00

Consensus revenue estimates fall to kr.30.0m

Full year 2020 earnings released: kr.0.30 loss per share (vs kr.0.41 loss in FY 2019)

Bioporto A/S Provides Earnings Guidance for the Year 2021

BioPorto Provides Pipeline Update

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New 90-day high: kr.6.24

New 90-day high: kr.4.07

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Third quarter 2020 earnings released: kr.0.09 loss per share